-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target

Benzinga·09/14/2026 12:38:16
Listen to the news
Wedbush analyst Robert Driscoll reiterates Crescent Biopharma (NASDAQ:CBIO) with a Outperform and maintains $27 price target.